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Abstract
Background: Duchenne muscular dystrophy (DMD) is caused by mutations in the DMD gene, which codes for the
dystrophin protein. While progress has been made in defining the molecular basis and pathogenesis of DMD, major
gaps remain in understanding mechanisms that contribute to the marked delay in cardiac compared to skeletal
muscle dysfunction.
Methods: To address this question, we analyzed cardiac and skeletal muscle tissue microarrays from golden
retriever muscular dystrophy (GRMD) dogs, a genetically and clinically homologous model for DMD. A total of 15
dogs, 3 each GRMD and controls at 6 and 12 months plus 3 older (47–93 months) GRMD dogs, were assessed.
Results: GRMD dogs exhibited tissue- and age-specific transcriptional profiles and enriched functions in skeletal but
not cardiac muscle, consistent with a “metabolic crisis” seen with DMD microarray studies. Most notably, dozens of
energy production-associated molecules, including all of the TCA cycle enzymes and multiple electron transport
components, were down regulated. Glycolytic and glycolysis shunt pathway-associated enzymes, such as those of
the anabolic pentose phosphate pathway, were also altered, in keeping with gene expression in other forms of
muscle atrophy. On the other hand, GRMD cardiac muscle genes were enriched in nucleotide metabolism and
pathways that are critical for neuromuscular junction maintenance, synaptic function and conduction.
Conclusions: These findings suggest differential metabolic dysfunction may contribute to distinct pathological
phenotypes in skeletal and cardiac muscle.
Keywords: Duchenne, BDNF, Muscular dystrophy, Cardiac, Dystrophin, Metabolism
Background
Duchenne muscular dystrophy (DMD) and the genetically
homologous mdx mouse and golden retriever muscular
dystrophy (GRMD) dog models are caused by mutations
in the DMD gene, resulting in severely reduced or absent
dystrophin protein [1–5]. Despite being genetically hom-
ologous, the three diseases demonstrate distinct pheno-
types, with DMD and GRMD being more severe [4, 6].
Gene expression in mdx mice and DMD patients is also
distinctive. By 16 weeks of age, the mdx transcriptome is
relatively quiescent [7], while DMD expression profiles
demonstrate a so-called “metabolic crisis” [8, 9]. Meta-
analysis of gene expression datasets from six different
studies of DMD skeletal muscle biopsies provide especially
strong evidence that thematic metabolic disturbances are
pathophysiologically relevant [10] and likely contribute to
muscle atrophy [11]. In support of this concept, therapies
that enhance metabolism, such as corticosteroids and
coenzyme Q, are temporarily beneficial.
In contrast to the early progressive wasting seen with
DMD skeletal muscle, the heart is relatively preserved,
with onset of cardiomyopathy typically occurring in the
second or third decade of life [12, 13]. How or why the
heart is temporarily spared is not understood, and predict-
ive markers for DMD cardiomyopathy are currently un-
available. As with skeletal muscle, the mdx and GRMD
models are distinctive. As with DMD, GRMD dogs have
progressive skeletal muscle weakness and late-onset
cardiomyopathy [5, 14–16], while the mdx mouse exhibits
subtle cardiac abnormalities [6]. We hypothesized that
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differences in cardiac and skeletal muscle metabolism
contribute to this variable disease progression. To address
this hypothesis, we studied a group of GRMD dogs that
were previously shown to have altered expression of
osteopontin (OPN) and brain-derived neurotropic fac-
tor (BDNF) in dystrophic skeletal and cardiac muscles,
respectively [17]. These findings were subsequently
translated to boys with DMD, demonstrating that circu-
lating levels of OPN and BDNF correlated with skeletal
muscle function or cardiac dysfunction [17]. Building
on this work in the current study, we found strikingly
different metabolic gene expression patterns in cardiac
and skeletal tissue, providing further insight into potential
molecular mechanisms underlying tissue-specific disease
progression.
Methods
Animals
The study was approved by the Institutional Animal
Care and Use Committee at the University of North
Carolina at Chapel Hill. All dogs were used and cared
for according to principles outlined in the National
Research Council Guide for the Care and Use of Labora-
tory Animals. The GRMD genotype was suspected based
on elevated serum creatine kinase and confirmed by
genotyping. Affected dogs subsequently developed char-
acteristic clinical signs. Notably, the GRMD phenotype
progresses dramatically over the 3 to 6 month age period
and then tends to stabilize [18, 19]. Given the relative
equivalency of the first year of a golden retriever’s life to
the initial 20 years for a human [20], the 3 to 6 month
period for GRMD corresponds to an analogous period
of deterioration between ages 5 and 10 years in DMD
[21–23]. A total of 15 dogs were included in the study: 3
each 6–7.5 and 12–13 month-old GRMD dogs and 6
age-matched (littermate) wild type controls, plus 3 older
(47, 52, and 93 month-old) GRMD dogs. Samples from
the medial head of the gastrocnemius (MHG) and left
ventricular (LV) free wall were removed at necropsy and
processed. Muscle sections were snap frozen in a Freon
substitute, cooled in liquid nitrogen, stored at -80 °C and
then shipped in cryovials to Vanderbilt for analysis.
Microarrays
Total RNA was isolated from the LV and MHG of the 15
dogs according to the manufacturer’s protocol (Qiagen,
Germantown, MD). Quality assessment of RNA, further
processing, and data acquisition were performed by the
GSR Microarray Core at Vanderbilt. Affymetrix Canine
Gene 1.0 Expression arrays (Affymetrix, Inc., Santa
Clara, CA) were used, two arrays per animal (for paired
LV and skeletal muscle samples), for a total of 30 ar-
rays. Raw data were RMA normalized, followed by
ANOVA with Benjamini & Hochberg correction, using
Partek Genomics Suite 6.6 (Partek Incorporated, St. Louis,
MO). Genes with a p value (with or without FDR) < 0.05
and fold-difference > 1.5 were considered significantly al-
tered. Normalized and raw data generated from canine
gene expression arrays were deposited under Accession
Number GSE68626 in the Gene Expression Omnibus
(GEO), available through NCBI (http://www.ncbi.nlm.
nih.gov/geo/)GEO. Functional and pathway enrichment
analyses were conducted using Ingenuity Pathway Ana-
lysis (IPA, Qiagen, Germantown, MD), Partek Genomics
Suite 6.6 (Partek Incorporated, St. Louis, MO), DAVID
Bioinformatics Resources 6.8 [24, 25],or Gene Set Enrich-
ment Analysis (GSEA) desktop freeware version 2.2.3
(BROAD Institute). For GSEA using Partek software,
normalized signal values were used. For GSEA using
BROAD software, differentially expressed genes were first
separated by directionality (up-regulated genes and
down-regulated gene) and the subsequent lists ranked
by p value, where ranked score = -log(p value).
Western blot analysis
Western blot analysis was performed as previously
described [26]. Primary antibodies used were rabbit
anti-AMPK (total and phosphorylated, Cell Signaling
Technologies, Inc., Danvers, MA) and rabbit anti-p90
(Cell Signaling Technologies) as a loading control.
Statistics
All data are expressed as means ± SEM. Comparisons
made between two variables were performed using a
Student t test unless otherwise stated. P values of less
than 0.05 were considered statistically significant. For
gene microarray analysis, data were uploaded into Partek
Genomics Suite version 6.6 (Partek Incorporated, St.
Louis, MO) and RMA normalized before further ana-
lysis. Partek was used to perform pairwise comparisons
of average group values and one-way ANOVA for the
eight groups. Only probes that resulted in a fold-change
of at least 1.5 and p value of less than 0.05 were considered
significantly altered.
Results
GRMD gene expression findings: an overview
A total of 30 samples from 15 dogs were included in
the study, divided according to disease-state (GRMD
or wild type) and tissue type (skeletal [MHG] muscle
or cardiac [LV] muscle). We focused primarily on 12
dogs at ~6 months or 12 months, for which there
were a total of 8 groups with 3 biological replicates
each. Based on a non-stringent and straightforward
analysis of age-matched and wild type samples, we com-
piled a single list of 5,835 probes that were significantly
differential (p value < 0.05, fold-difference > 1.5) between
GRMD and wild type tissues for at least one of the four
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comparisons (Additional file 1: Table S1). An overview of
statistical results is shown in Fig. 1e. The most immedi-
ately obvious distinction among the tissues was the overall
difference in gene expression profiles between the 6 and
12-month GRMD age groups. Whereas there were rela-
tively few expression differences between LV samples at
these two ages when compared to wild type control
animals, MHG samples from these same dogs exhibited
dramatic differences (Fig. 1). This is consistent with the
more dramatic progression of skeletal muscle disease
up to 6 months of age with subsequent stabilization,
while cardiac muscle function is typically normal over
this period. Hierarchical clustering of all 5,835 probes
also indicated that the global transcriptional profile of
GRMD MHG at 6 months was unique and distinct
from all other samples, including GRMD MHG at
12 months (Additional file 2: Figure S1).
Similar to what has been reported elsewhere for
DMD and animal models [27–29], up-regulated skeletal
muscle genes included those associated with fibrosis
(e.g., collagens, POSTN, TIMP1), inflammation (e.g.,
complement components, chemokines, cytokines), and
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Fig. 1 Volcano plots are shown highlighting gene expression differences between dystrophic medial head of the gastrocnemius (MHG) skeletal
muscle of golden retriever muscular dystrophy (GRMD) dogs at 6 (a) and 12 (b) months (m), as well as GRMD left ventricle (LV) from 6 (c) and 12
(d) month-old dogs, each compared to their respective wild type controls. The y-axis displays p values, and fold-differences are plotted on the
x-axis for GRMD versus control dogs for each of the four comparisons. Each circle represents an individual probe set (gene) and is colored based
on fold-difference (blue for genes with lower expression in GRMD dogs, red for genes with higher expression values, and gray for no change), as
shown in the legend. Orange lines mark significance cut-off values (p value < 0.05, fold-difference > 1.5). Panel (e) shows a matrix including the
number (No.) of array signal intensity probes deemed as significantly differential (p value < 0.05, fold-difference > 1.5) between pairs of groups.
Pairwise comparisons include GRMD versus wild-type (WT) dogs for matched skeletal muscle (MHG) and LV tissue of dogs aged 6 months and
12 months. Pairwise comparisons of the two age groups for each tissue are also shown
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Table 1 Functional analysis results of GRMD-induced gene alterations
GO Biological Process/Pathway MHG at 6 m LV at 6 m
No NES p val No NES p val
Actin filament organization 36 1.91 0.001 -
Regulation of extrinsic apoptotic pathway 37 1.70 0.001 -
Regulation of cytoskeleton organization 31 1.79 0.0021 -
ECM disassembly 20 1.78 0.0064 -
Endothelial cell differentiation 15 1.77 0.0078 -
Regulation of actin filament organization 57 1.64 0.0081 -
Protein localization to organelle 55 1.58 0.006 -
Inflammatory response 100 1.55 0.002 -
Stem cell differentiation 24 1.54 0.0305 -
Positive regulation of cell-substrate adhesion 24 1.54 0.0369 -
Regulation of ion homeostasis 32 1.52 0.0327 -
Immune system process 369 1.50 0.001 -
Endocytosis 111 1.50 0.006 -
Regeneration 36 1.50 0.0369 -
Muscle structure development 51 1.46 0.0433 -
Regulation of cell-cell adhesion 74 1.45 0.025 -
Angiogenesis 58 1.44 0.0351 -
Cell motility 167 1.43 0.008 -
Regulation of cell proliferation 233 1.39 0.012 19 ns
Regulation of cell differentiation 206 1.38 0.013 20 ns
Cellular macromolecule localization 149 1.35 0.028 -
Oxidation reduction 98 −2.82 0.001 16 ns
Carboxylic acid catabolism 29 −2.58 0.001 -
Generation of precursor metabolites and energy 45 −2.45 0.001 -
Cellular respiration 24 −2.44 0.001 -
Mitochondrion organization 73 −2.35 0.001 -
Organonitrogen compound metabolism 153 −2.24 0.001 28 ns
Coenzyme metabolism 39 −2.23 0.002 -
Small molecule metabolism 176 −2.20 0.001 30 ns
Catabolic process 142 −2.18 0.001 19 ns
Hexose metabolism 22 −2.12 0.0042 -
Glucose metabolism 21 −2.05 0.0058 -
Regulation of ketone metabolism 26 −2.05 0.002 -
Cofactor metabolism 46 −1.93 0.0038 -
Macroautophagy 27 −1.93 0.0039 -
Nitrogen compound transport 31 −1.93 0.0118 -
Protein ubiquitination 63 −1.88 0.0062 -
Organophosphate metabolism 84 −1.86 0.0117 -
Small molecule biosynthesis 48 −1.85 0.0096 -
NTP metabolism 21 −1.82 0.0081 -
Autophagy 33 −1.79 0.022 -
Cellular amino acid catabolism 21 −1.78 0.0135 -
Alpha amino acid catabolism 17 −1.74 0.0259 -
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muscle cytoskeletal proteins (e.g., myosin heavy chains,
troponins, and actins). The most profoundly down-
regulated genes were those associated with muscle growth
and development (e.g., CLCN1, MYLK2, MYBPC2, and
MSTN). There were surprisingly few genes (9.6%) that
were differentially expressed between GRMD and wild
type MHG tissue in both of the ages evaluated. The
majority of these genes were altered more profoundly in
the younger GRMD dogs relative to wild type controls.
Embryonic and perinatal forms of myosin heavy chains
(MYH3 and MYH8) for instance were up-regulated
180-fold and 61-fold in MHG at 6 months, compared
to 6-fold and 7.4-fold in 12-month-old dogs, respect-
ively. Up-regulated genes with a higher magnitude of
increase in MHG from 12- versus 6- month-old GRMD
dogs included those encoding adult myosin heavy
chains, extracellular matrix components, parvalbumin,
and β-1-syntrophin (SNTB1).
Cardiac expression differences included genes with
disease-associated functions, such as muscular disorders,
cardiovascular disease, and organismal injury. To iden-
tify non-directional (up or down) and non-age related
(i.e., those altered at either age) functional patterns, we
used Ingenuity Pathway Analysis software to analyze
genes differentially expressed between GRMD versus
control dogs. As shown in Additional file 3: Table S2,
several over-represented functional categories were
specific to genes altered in skeletal muscle (up- or
down-regulated in GRMD versus wild type dogs at ei-
ther age). For instance, multiple genes important for
regulation of cell death (170 genes, p value = 0.0001) and
membrane organization (85 genes, p value = 0.0041)
were significantly perturbed in MHG but not LV tissues
in GRMD. This functional signature supports the idea
that tissue-dependent gene expression alterations drive
differences in disease between the two muscle types.
Genes important for metabolism and energy production
were likewise restricted to skeletal muscle (Additional
file 3: Table S2), consistent with the notion that a
metabolic phenotype contributes to dystrophic skeletal
muscle disease progression.
We also performed a more comprehensive gene set
enrichment analysis (GSEA) of each relevant list of
differential genes (age- and tissue-matched pairwise
comparisons). The most significantly enriched biological
processes for genes more highly expressed in 6 month
GRMD MHG relative to controls included actin filament
organization inflammation (36 genes, relative enrich-
ment score (NES) = 1.9), ECM disassembly (20 genes,
NES = 1.8), inflammation (100 genes, NES = 1.6, stem
cell differentiation (24 genes, NES = 1.5), muscle struc-
ture development (51 genes, NES = 15), and angiogenesis
(58 genes, NES = 1.4) (Table 1). Down-regulated genes
(those more highly expressed in normal dogs compared
to GRMD at 6 months) were almost exclusively associated
with metabolism (Table 1), including oxidation reduc-
tion (98 genes, NES = -2.6), generation of precursor
metabolites and energy (45 genes, NES = -2.5), cellular
respiration (24 genes, NES = -2.4), mitochondrion
organization (73 genes, NES = -2.4), and glucose metab-
olism (21 genes, NES = -2.1). For the most part, down-
regulated functional categories were more significant
Table 1 Functional analysis results of GRMD-induced gene alterations (Continued)
Macromolecule metabolism 60 −1.71 0.0279 -
Anion transmembrane transport 21 −1.63 0.041
Carbohydrate metabolism 63 −1.62 0.0299 -
Acyl-CoA metabolism 18 −1.62 0.0433 -
Regulation of transport 120 ns 19 −2.11 0.001
MHG at 12 m LV at 12 m
No NES p val No NES p val
DNA metabolism 18 1.80 0.0045 -
Lipid biosynthesis 15 1.66 0.0216 -
Cell projection organization 37 1.62 0.0249 -
Cellular response to stress 38 1.62 0.0227 -
Cell proliferation 19 1.53 0.0473 -
Regulation of cellular protein localization 22 1.53 0.0378 -
Regulation of organelle organization 33 1.50 0.041 -
Regulation of transport - 19 −1.76 0.013
Functional analysis was performed using GSEA software, as detailed in the methods section. Positive and negative NES values respectively represent pathways
enriched or down-regulated in GRMD animals compared to healthy counterparts. Nominal p values (p val) are shown, as are overlapping categories in skeletal
(MHG) and left ventricular (LV) tissues for animals aged 6 months (6 m, top part of table) and 12 m (lowermost art of table). GO = gene ontology. No = number of
differentially expressed genes in the category listed. NES = normalized (or relative) enrichment score. ns = not significant
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(lower p value, higher magnitude of NES) than up-
regulated ontologies. Most notably, however, there was
a clear lack of “functional variety” in down-regulated
genes (i.e., a catabolic theme) that was not observed for
genes more highly expressed in MHG of 6 month-old
GRMD (Table 1).
Surprisingly, these enriched functions were not recapit-
ulated in 12 month-old animals. The most significantly
enriched functional categories of genes up-regulated in
MHG from these older animals were DNA metabolism
and lipid biosynthesis (Table 1). Significantly enriched
functional categories observed in MHG of 6 month-old
dogs were likewise not observed in LV at either age
(Table 1). Only one biological process, regulation of trans-
port, was significantly enriched in LV of GRMD at either
age (19 genes, NES = -2.1 and -1.8 at 6 months and
12 months, respectively).
Skeletal muscle-specific transcriptional profile: the meta-
bolic phenotype
A direct comparison of age-matched MHG and LV
tissues resulted in large lists of differentially expressed
genes consistent with known differences in these two
tissue types, as expected (Additional file 4: Figure S2).
To eliminate those gene expression changes driven pri-
marily by tissue specificity, we instead compared GRMD
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to normal for LV and MG tissues and used those separ-
ately generated lists to find GRMD driven differences
between the two tissue types. To identify GRMD skel-
etal- and cardiac muscle-specific gene expression pro-
files, we compared the most significantly altered genes
in GRMD MHG and LV at 6 months of age. For this
analysis, we chose a more stringent significance cutoff
(p value < 0.01 and 2-fold) to eliminate potentially false
positive differences between GRMD-mediated changes
in the two tissue types, such as p value = 0.049 for the
MHG comparison and p value = 0.051 for the same
comparison in LV for example). Based on these criteria,
there were a total of 1,172 annotated genes that were
altered in MHG from young GRMD dogs which were
unchanged in matched LV samples. The majority of
these (893 transcripts) were up-regulated in GRMD
dogs relative to wild type controls, with only 279 more
highly expressed in the wild type control animals.
Multiple pathways were associated with genes more
highly expressed in 6 month GRMD MHG, including
those related to inflammation (e.g., leukocyte migration,
chemokine signaling, complement and coagulation cas-
cades, phagocytosis, Toll-like receptor signaling), cyto-
skeletal regulation, ECM interaction/adhesion, cell
cycle, platelet activation, growth and survival signaling
pathways (e.g., NF-κB, p53, PI3K- Akt) and catabolic me-
tabolism (e.g.,. lysosome, glycan degradation) (Additional
file 5: Figure S3). Pathways for down-regulated genes
(those more highly expressed in MHG of 6 month-old
normal dogs relative to GRMD), on the other hand were
almost exclusively metabolic (e.g., TCA cycle, fatty acid
biosynthesis and degradation, AMPK signaling, glycolysis/
Fig. 4 Diagram of glycolysis is shown, including enzymes whose transcripts were more highly expressed in GRMD (red) or wild type dogs (green).
Metabolic transporters are also shown. The information was compiled using various public databases, and the figure was produced using Protein
Lounge pathway builder software (ePath3D). The hemoglobin molecule was obtained from the Protein Databank (www.rcsb.org). The embedded
dog illustration showing dystrophic musculature (top left) is an original work of art produced by Dave Carlson (Carlson-Art.com). Note: Common
protein symbols are shown, some of which are represented by several different synonyms or have different names for their respective transcripts.
For instance, MCP1 and 2 are also called BP44 and BP44L. PFK2 is encoded by PFKFB3
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gluconeogenesis, amino acid metabolism, insulin signaling)
(Additional file 6: Figure S4). MHG from 12 month-old
GRMD included pathways that were similar to, albeit fewer
than, those found in younger dogs for both up- and down-
regulated genes (Additional file 7: Figure S5).
Consistent with functional and pathway analyses, man-
ual examination of MHG-specific genes revealed a meta-
bolic pattern consistent with a general perturbation of
multiple metabolism and energy production pathways.
For example, three out of four of the pyruvate dehydro-
genase subunits were down-regulated, along with most
of the TCA cycle enzymes and several electron transport
chain components (Fig. 2). Conversely, the gene encod-
ing ATP citrate lyase (ACLY), which functions counter
to the other TCA cycle enzymes by synthesizing acetyl-
CoA, was up-regulated, as was the transcript for the
mitochondrial membrane potential de-coupler 2 (UCP2)
that un-couples oxidative phosphorylation from ATP
synthesis with energy instead dissipated as heat (Fig. 2).
Multiple lysosome enzymes were also up-regulated in
GRMD skeletal muscle (Fig. 3), possibly as a re-salvage
energy source, and the glycolytic pathway and associated
shunts were altered (Fig. 4) suggesting conversion to
alternative energy sources instead of, or in addition to,
glycolysis. Our findings were consistent with dysregula-
tion of the AMPK pathway, which when activated in
muscle contributes to a slower, more oxidative pheno-
type. Indeed, the gene encoding the catalytic subunit
of AMPK (PRKAA2, p value 3.7 × 10−6, -2.3-fold) was
down-regulated in GRMD MHG, as was the gene
encoding the important downstream effector, PGC-1α
(PPARGC1A, p value 9.6 × 10−3, -2.0-fold). We con-
firmed down-regulation of AMPK in GRMD skeletal
muscle by Western blot analysis (Fig. 5) but did not
find any difference in the phosphorylation status of
AMPK in these same tissues. The AMPK levels in
GRMD dogs were significantly lower than those from
respective normal controls. AMPK levels were lower
in the older (47–93 months) versus younger GRMD
dogs, although this difference was not significant. Sur-
prisingly, protein levels of AMPK were undetectable
in matched cardiac tissue from these same animals
(data not shown).
Interestingly, GLUT4, which encodes an insulin-
regulated facilitative glucose transporter, was also sig-
nificantly down-regulated in MHG from 6 month-old
dogs. This is likely an important finding, given the pre-
viously suggested role of GLUT4 alterations in insulin
resistance in DMD patients [30].
Cardiac muscle-specific transcriptional profile: the
peroxisomal bypass
In contrast to skeletal muscle findings, the expression
levels of the genes encoding AMPK and PGC-1α were
unaltered in LV tissues from 6 and 12-month-old
GRMD dogs when compared to age-matched controls,
despite alteration in 5 genes associated with the
AMPK signaling pathway in the older animals (Additional
file 8: Figure S6). Similarly, mass down-regulation of
critical energy production genes was not observed for LV
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Fig. 5 a Western blots for p-AMPK, total AMPK and p90 (loading control) in skeletal muscle tissues of GRMD and normal (wild type) dogs, including
the three older GRMD dogs (47, 52, and 93 months-old) [17], are shown. b Bar graph showing semi-quantification of Western blot results for p-AMPK
and AMPK, as calculated by densitometry, for skeletal muscle tissues from normal dogs aged 6 (black bars) or 12 (white bars) months, and GRMD dogs
aged 6 (red bars), 12 (orange bars), or 47–93 (green striped bars) months. Asterisks indicate significance (*p < 0.05, **p < 0.01)
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tissue, nor was there up-regulation of multiple lysosomal
genes. En bloc down-regulation of genes involved in
peroxisome-specific beta-oxidation and uric acid produc-
tion was, instead, seen in parallel with the up-regulation
of key entry points for mitochondrial-based energy
production (Fig. 6). Interestingly, the NT5C gene encoding
cytosolic 5′,3′-pyrimidine nucleotidase (also called deoxy-
5′-nucleotidase, or dNT-1) was up-regulated in GRMD
versus wild type dogs, concomitant with down-regulation
of genes encoding enzymes that function up-stream and
downstream of NT5C (Fig. 7). While interpretation of
these enzymatic changes would require further experi-
mentation, two possible consequences might include ac-
cumulation of adenosine in the dystrophic heart (but not
skeletal muscle) and up-regulation of uric acid production
in dystrophic skeletal muscle (but not in the heart).
Discussion
Duchenne muscular dystrophy is characterized by striking
temporal differential involvement of cardiac and skeletal
muscles [31], despite shared dystrophin protein deficiency
and similar physiological functions in the two muscle
types. The GRMD model provides an excellent platform
for studying human DMD, largely because of the remark-
able level of similarity between dogs and humans in gen-
eral (e.g., in body structure) as well as likenesses in DMD/
GRMD disease features [16]. In this study, we endeavored
to discern whether the distinct cardiac and skeletal pheno-
types in GRMD (and, by extension, DMD) are associated
with differential gene expression within the respective
muscle groups. By evaluating distinct ages representing
different stages of GRMD disease, and two different tissue
types historically observed to show contrasting levels of
disease over this period, we were able to compare expres-
sion profiles in context with disease state [19].
The global transcriptome of MHG but not LV from
6 month-old GRMD dogs was profoundly altered. How-
ever, consistent with subsequent relative stabilization of
skeletal muscle disease, these early expression changes
were not sustained at 12 months. Looking more specific-
ally at metabolic pathways in MHG from 6-month-old
GRMD dogs, we identified a gene expression signature
Fig. 6 Diagram of peroxisomal beta-oxidation and other metabolic changes observed in GRMD LV tissues is shown. Proteins shown represent
up-regulation (red) or down-regulation (green) of associated transcripts in dystrophic dogs as compared to normal controls
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consistent with a “metabolic crisis” in DMD studies [9].
This canonical expression signature was entirely absent
from matched GRMD LV tissues. Thus, our findings
suggest differential metabolic dysfunction may contribute
to distinct pathological phenotypes in these two muscle
types. The most obvious transcriptional alterations that
could contribute to metabolic dysfunction were down-
regulation of dozens of energy production-associated mol-
ecules, most notably all of the TCA cycle enzymes and
multiple electron transport components. Likewise, the
majority of glycolytic pathway-associated enzymes were
altered in a manner consistent with shunting of glycolytic
molecule intermediates into alternative pathways, such as
the anabolic pentose phosphate pathway. This is consist-
ent with generalized muscle atrophy of any cause [11] and
DMD in particular [29].
Gene expression alterations in MHG muscle from
GRMD dogs also suggested that the Rappaport-
Leubering Shunt was interrupted. For example, there
was down-regulation of the gene encoding bisphosphogly-
cerate mutase (BPGM), the enzyme that produces 2,3
bisphosphoglycerate (2,3-BPG), an allosteric effector
which enhances release of oxygen from hemoglobin
to the tissues. Multiple inositol-polyphosphate phos-
phatase 1 (MINP1), whose product converts 2,3-BPG
to 2-phosphoglycerate, was instead up-regulated. De-
crease in 2,3-BPG levels could lead to impaired tissue
oxygenation, such as that observed in iron deficient
anemia or chronic respiratory disease with hypoxia.
Consistent with this hypothesis, we also observed a small
but significant reduction (1.4-fold, p value = 0.006) in the
myoglobin gene in MHG (but not LV) tissues of GRMD
animals.
Conclusions
When considered together, these various gene expres-
sion alterations provide a plausible mechanism for meta-
bolic changes observed in the clinical setting. Lowered
glucose uptake and glycolytic changes may contribute to
insulin resistance. Impaired tissue oxygenation, along
with a reduction in TCA and electron transport energy
production, would support a shift from aerobic to anaer-
obic respiration, causing in essence a Warburg effect. In
concert, these metabolic events, paired with the high-
energy demands of regenerating muscle, almost certainly
contribute to disease progression. In summary, this
study provides novel insight into the metabolic gene
expression profile of dystrophic cardiac tissue, which is
unique from matched skeletal muscle of GRMD dogs.
Further, these findings suggest a plausible mechanistic
explanation for the chronological pattern of disease in
these two different muscle types.
Additional files
Additional file 1: Table S1. Statistically significant gene list. Column A=
Affymetrix unique probe set ID, Column B = Gene ID, Column C= gene
symbol, Column D= RefSeq ID, Column E = gene assignment, Column F =
gene title, Column G= gene symbol, Column H= ANOVA-generated p values
for all groups, Column I = ANOVA-generated p values for comparison of left
ventricular (LV) tissues from 6 month-old (6 m) Golden Retriever Muscular
Dystrophy (GRMD) dogs versus LV from 6 m normal controls, Column J = Fold
difference for [LV 6 m GRMD/LV 6 m normal], Column K = ANOVA-
generated p values for comparison of LV 12 m GRMD versus LV 12 m
normal, Column L = Fold difference for [LV 12 m GRMD/LV 12 m
normal], Column M = ANOVA-generated p values for comparison of
medial head of the gastrocnemius (MG) from 6 m GRMD versus MG
6 m normal, Column N = Fold difference for [MG 6 m GRMD/MG 6 m
normal], Column O = ANOVA-generated p values for comparison of MG
12 m GRMD versus MG 12 m normal, Column P = Fold difference for
[MG 12 m GRMD/MG 12 m normal]. Gene annotations were obtained
within Partek (Columns B-C) and using Affymetrix NetAffx database
information (Columns D-G). (XLSX 995 kb)
Additional file 2: Figure S1. Hierarchical clustering of 5,835 significantly
altered transcripts is shown. Rows represent individual samples, labeled
according to group, and columns represent individual transcripts. Bright red,
a
b
Fig. 7 Diagram of nucleic acid gene expression differences in
GRMD versus wild type dogs is shown. Panel a, Small red heart
icons are shown below the names of enzymes whose transcripts
were more highly expressed in LV of GRMD compared to wild
type dogs. Green heart icons accompany those encoded by
genes that were more highly expressed in wild type versus
GRMD dogs. Panel b, Small skeletal muscle icons are shown
below the names of enzymes whose transcripts were more
highly expressed in MHG of GRMD compared to wild type
dogs (red) or in wild type versus GRMD dogs (green)
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bright blue and gray represent highest, lowest and median normalized and
scaled signal intensity values, respectively. (DOCX 116 kb)
Additional file 3: Table S2. Functional analysis results of GRMD-
induced gene alterations. MHG =medial head of the gastrocnemius,
LV = left ventricle, B-H p val = Benjamini & Hochberg-corrected p value,
No. = number of differentially expressed genes in the given functional
category, ns = not significant, Dash (“-”) indicates not identified in the
analysis. (DOCX 16 kb)
Additional file 4: Figure S2. Volcano plot is shown highlighting gene
expression differences between dystrophic left ventricle (LV) and medial
head of the gastrocnemius (MHG) skeletal muscle of golden retriever
muscular dystrophy (GRMD) dogs at 6 months. The y-axis displays p values,
and fold-differences are plotted on the x-axis for comparison of GRMD LV
versus MHG (LV/MHG). Each circle represents an individual probe set (gene)
and is colored based on fold-difference (blue for genes with lower expression
in GRMD MHG and higher expression in LV, red for genes with higher
expression values in LV and lower in MHG, and gray for no change), as
shown in the legend. Orange lines mark cut-off values (p value < 0.05, fold-
difference > 2). Official gene symbols are indicated to highlight major
expression differences between LV and MHG. (PPTX 136 kb)
Additional file 5: Figure S3. Plot shows over-represented pathways for
genes up-regulated in 6 m GRMD MHG. Statistical significance (smaller p
values = larger numbers = greater significance) is shown on the x-axis,
and numbers of genes altered per pathway is shown to the right of each
bar. (DOCX 32 kb)
Additional file 6: Figure S4. Plot shows over-represented pathways for
genes down-regulated in 6 m GRMD MHG. Statistical significance (smaller
p values = larger numbers = greater significance) is shown on the x-axis,
and numbers of genes altered per pathway is shown to the right of each
bar. (DOCX 35 kb)
Additional file 7: Figure S5. Plot shows over-represented pathways for
genes up- (red bars) or down-regulated (green bars) in 12 m GRMD
MHG. Statistical significance (smaller p values = larger numbers = greater
significance) is shown on the x-axis, and numbers of genes altered per
pathway is shown to the right of each bar. (DOCX 30 kb)
Additional file 8: Figure S6. Plot shows over-represented pathways for
genes altered in 6 m (light blue bars, top) or 12 m (dark blue bars, bottom)
GRMD LV. Statistical significance (smaller p values = larger numbers = greater
significance) is shown on the x-axis, and numbers of genes altered per
pathway is shown to the right of each bar. AMPK signaling pathway
genes are shown below the corresponding pathway bar, colored based
on directionality (red for up-regulation and green for down-regulation,
respectively in GRMD versus normal dogs). (DOCX 26 kb)
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